MedTrace Logo

Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function

NCT02304081 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2018-06-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate alpha- and beta-cell function during combination treatment with saxagliptin in addition to dapagliflozin and metformin compared to placebo in addition to dapagliflozin and metformin in subjects with T2DM on stable metformin background therapy.

Conditions

  • Type2 Diabetes Mellitus

Interventions

DRUG

Saxagliptin

competitive inhibitor of human dipepitdylpeptidase (DPP)-IV

DRUG

Placebo for Saxagliptin

Sponsors & Collaborators

  • Prof. Dr. Thomas Forst

    lead INDUSTRY

Principal Investigators

  • Thomas Forst, Prof. Dr. · Profil Mainz GmbH & Co KG, Rheinstraße 4c, 55116 Mainz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02304081 on ClinicalTrials.gov